NEW YORK (
CHANGE IN RATINGS
was upgraded at Bank of America/Merrill Lynch to neutral. $60 price target. Company is seeing a pricing overhang easing in Florida, BofA/Merrill said.
was downgraded at Stifel Nicolaus to hold from buy. Valuation call, given low expectations for production growth, Stifel Nicolaus said.
was upgraded at DA Davidson to buy from neutral. Company is leveraged to a recovering nonresidential construction environment, DA Davidson said.
downgraded at Piper Jaffray to neutral from overweight. $14 price target. Company lacks exposure to new product cycle in display.
was upgraded at Bank of America/Merrill Lynch to buy from neutral. $81 price target. Company offers a strong secular growth story, BofA/Merrill said.
Johnson & Johnson
was upgraded at Goldman Sachs to neutral from sell. Pharma outlook is improving, Goldman said. $95 price target.
was downgraded to hold at TheStreet Ratings.
was downgraded at Jefferies to underperform from buy. Estimates were also lowered, given worsening business environment and disappointing R&D productivity, Jefferies said. $40 price target.
was downgraded at Credit Suisse to neutral from outperform. $64 price target. Comp weakness persists and inventories are building, Credit Suisse said.
was downgraded at Jefferies to hold from buy. Estimates were also decreased on weak business environment and unimpressive cost-cutting initiatives, Jefferies said. $50 price target.
was upgraded at Goldman Sachs to buy from neutral. $170 price target. ibruttinib could generate $7.5 billion of peak annual sales, Goldman said.
was downgraded to sell at TheStreet Ratings.
was downgraded at Goldman Sachs to sell from neutral. Company will likely grow slower than its peers over the next few quarters, Goldman said.
Stock Comments / EPS Changes
estimates, price target were reduced at UBS. Estimates were reduced through 2014. Company lowered its guidance, UBS said. Buy rating and new $22 price target.
estimates, target upped at Credit Suisse. Estimates were boosted through 2015. Higher comp sales are driving gross margin expansion. Outperform rating and new $55 price target, Credit Suisse said.
estimates, price target were raised at UBS. Shares are now seen reaching $59. Estimates were also increased, as the company is seeing higher reference pricing, UBS said. Buy rating.
Read: Here's Where Your Neighbors Like to Have Sex
estimates were increased at Jefferies. Elpida and DRAM ASPs contributing to income and gross margin, Jefferies said. Buy rating and $30 price target.
Micron estimates, price target were increased at UBS. DRAM pricing is moving higher, UBS said. Buy rating and new $23 price target.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.